Cargando…
Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
Intravenous immunoglobulin (IVIG) is used as an immunomodulatory agent in the treatment of various autoimmune/inflammatory diseases although its mechanism of action remains elusive. Recently, nonfucosylated IgG has been shown to be preferentially bound to Fcγ receptor IIIa (FcγRIIIa) on circulating...
Autores principales: | Mimura, Yusuke, Mimura-Kimura, Yuka, Saldova, Radka, Rudd, Pauline M., Jefferis, Roy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831331/ https://www.ncbi.nlm.nih.gov/pubmed/35154135 http://dx.doi.org/10.3389/fimmu.2022.818382 |
Ejemplares similares
-
Erratum: Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
Publicado: (2022) -
Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity
por: Smith, Alyson J., et al.
Publicado: (2023) -
Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity
por: Peschke, Benjamin, et al.
Publicado: (2017) -
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy
por: Mimura, Yusuke, et al.
Publicado: (2017) -
Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases
por: Dekkers, Gillian, et al.
Publicado: (2018)